Thyrocare Q1 FY26 – Testing Profits, Testing Patience, Testing CFOs

1. At a Glance

Thyrocare just diagnosed itself with a 59.9% YoY profit surge in Q1 FY26. Net profit: ₹38 Cr. Revenue? ₹193 Cr. And guess what? The CFO resigned right after approving the results. Coincidence or classic “mission accomplished” exit? Either way, the diagnostics company is back in growth mode, flexing a 30% OPM.

2. Introduction with Hook

Imagine a laboratory report that reads:

• Glucose: Normal
• Cholesterol: High
• CFO Resignation: Positive

Welcome to Thyrocare FY26! They’re running tests across the country faster than Gen Z runs from commitments—and now, they’ve added a leadership reshuffle as a cherry on top.

Key Stat #1: Q1 PAT up 60%.
Key Stat #2: OPM stable at a sexy 30%.
Key Stat #3: Stock is up 86% in a year. Someone’s wellness packages are working.

3. Business Model (WTF Do They Even Do?)

• Diagnostics, diagnostics, diagnostics.
• 92% revenue from testing—no side hustles, no distractions.
• 929 tests. 288 profiles. 43 “Aarogyam” wellness packages.
• Processes 3 billion investigations annually (yes, with a “b”).

Think of it as the Amazon of blood samples. Except no one’s happy to receive a parcel from them.

4. Financials Overview

Commentary:
OPM’s glowing like